lung cancer

News

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion.

News

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cance...

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now looks like it may be able to add lung, stomach and colorec

News

Roche's Tecentriq gains new first-line lung cancer use

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients.

News

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received the

News

Roche's TIGIT drug shows promise in untreated lung cancer

Roche has announced positive first phase 2 results from its new kind of cancer immunotherapy, showing that adding tiragolumab to its already approved Tecentriq creates a more potent combina

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cance...

Roche's Tecentriq gains new first-line lung cancer use

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

Roche's TIGIT drug shows promise in untreated lung cancer

AstraZeneca to unveil key data for cancer drugs at ASCO

AZ's gMG drug Klygefa nears EU approval

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks